treatment strategies for patients with idh1/2-mutated aml ineligible for intensive chemotherapy
Published 1 year ago • 404 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:15
outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
-
1:27
how do targeted treatments for idh1 and idh2 mutations work in acute myeloid leukemia (aml)?
-
1:48
idh1 inhibitor ivosidenib for the treatment of relapsed/ refractory aml
-
1:51
idh1/2 inhibitors for upfront aml therapy and transfusion independence
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:06:04
itp: novel treatments
-
4:16
how are high risk and low risk mds defined? #mds
-
4:10
explore idh mutations
-
1:39
optimizing chemotherapy in aml
-
0:45
optimizing chemotherapy combinations for aml
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
1:19
new treatments for aml
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
2:09
advances in the management of fit adults with aml
-
2:45
continuity of care for patients with hematological predispositions to aml
-
11:33
treatment algorithm for low-risk mds
-
1:17
combination therapy for the treatment of aml
-
5:01
treatment options for high-risk aml
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
1:36
targeted therapy for aml
-
1:14
pd1 inhibitors in patients with chl: the potential for combination therapies in earlier lines